Fireside chat: Sector Focus – Life Sciences
Global activity in the biopharma segment is due to rebound in 2023 as companies saw valuations dwindle, meaning that companies are now incentivised to acquire ‘cheap’ targets. According to Mergermarket data, the life sciences sector accounted for 13% of deal volume in Spain and 14% in Portugal last year. Life sciences was the most active sector for financial sponsors in Portugal last year. This session will review:
- What is driving activity in the life sciences sector in Iberia?
- Has activity rebounded in 2023 compared to 2022 due to ‘cheap’ targets?
- How are global macro-economic factors affecting activity in the sector?
- How are depressed public markets affecting the dealmaking pipeline in the sector?
Confirm cancellation
Something went wrong.
An error occurred trying to play the stream. Please reload the page and try again.
CloseSign-up to join the ION Analytics Community to:
- Register for events
- Access market insights
- Download reports
Raúl oversees and coordinates the identification and evaluation of investment opportunities from both scientific and business perspectives at Ysios Capital.
Prior to joining Ysios in 2008, Raúl first worked in corporate business development (Licensing In and Licensing Out) at Laboratorios Almirall. He was subsequently responsible for developing and managing the business of the Company in the Americas and Africa through licensees and distributors.
Raúl was initially trained as a researcher in central nervous system pharmacology within the Department of Pharmacology of the University of the Basque Country (UPV-EHU), and in neurochemistry within the Department of Neurochemistry at the Institute for Biomedical Research of the Barcelona–Spanish National Research Council (IIBB-CSIC).
Raúl holds a Bachelor’s degree in Biological Sciences from UPV-EHU, and a PhD in Neuroscience from UPV-EHU and the CSIC.
Board positions
Raúl is Chairman of Anaconda Biomed and Board Member at Synendos and CorWave. Formerly he was Board Member at STAT-Dx (acquired by Qiagen), Prexton Therapeutics (acquired by Lundbeck) and MedLumics.